Actionable mutations in non-small cell lung cancer in patients at hospital de Especialidades Eugenio Espejo, Ecuador 2017-2020.
Miguel Ángel Fernández FreireGabriela Isabel Gálvez SalazarMariana Meira ScudelerFernanda Rodrigues-SoaresGabriela Fernanda Jaramillo KoupermannAndrea Paola Moreno OcampoPublished in: Drug metabolism and personalized therapy (2022)
Our frequency mutations are concordant with those found in other studies in Latin America. EGFR was the most common biomarker mutation, and there was a better OS in EGFR non-mutated patient.